Compare Biogen Inc (BIIB) vs Global X Lithium & Battery Tech ETF (LIT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Biogen Inc vs Global X Lithium & Battery Tech ETF — how do they compare? Biogen Inc trades at $204.1 (market cap $30.13B), while Global X Lithium & Battery Tech ETF trades at $75.58. The key difference: Biogen Inc is trading nearer its 52-week high, Global X Lithium & Battery Tech ETF nearer its low. Which is the better fit depends on your goals.
| BIIB | LIT | |
|---|---|---|
Market Cap | $30.13B | — |
Sector | Health | Commodities - Metals/Agriculture |
52-Week High | $216.63 | $91.62 |
52-Week Low | $128.93 | $44.96 |
Enterprise Value | $37.20B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Biogen (BIIB) trades at $208.85, up 0.83% with bullish technical signals and strong institutional support. The company has delivered three consecutive earnings beats, with Q2 2026 EPS of $3.60 exceeding estimates by 22%. Recent acquisition of RayThera and raised 2026 guidance demonstrate strategic growth initiatives. Valuation metrics show a P/E of 36.21 and P/S of 3.01, while maintaining solid profitability with 73.99% gross margins.
Biogen presents a compelling investment case with strong earnings momentum and strategic acquisitions driving growth. However, investors face risks from declining legacy MS drug sales and net income margin compression from 16.86% in 2024 to 8.32% projected for 2026. The stock offers 12% upside to consensus price target of $234.47, supported by 62.5% analyst buy ratings.
LIT trades at $75.21, up 0.63% on the day, with a bullish technical signal from moving averages and oscillators. Recent news highlights strong momentum in the lithium and battery tech sector, driven by EV demand growth and China's 2030 NEV target. The stock has doubled over the past year, reflecting a rebound in lithium markets and positive sentiment around energy storage and semiconductor applications.
Outlook remains positive given sector tailwinds, but risks include reliance on EV adoption rates and potential oversupply. The stock's technical overbought condition near resistance at $75 suggests near-term consolidation may occur. Long-term growth is tied to global electrification trends and lithium market dynamics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Biogen Inc
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel MS drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogen's MS portfolio is co-promoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with SOBI) were spun off as part of Bioverativ in 2017. Biogen has several drug candidates in phase 3 trials in neurology and neurodegenerative diseases and has launched Spinraza with partner Ionis. Aduhelm was approved as the firm's first Alzheimer's disease therapy in June 2021.
Read more on BIIB →About Global X Lithium & Battery Tech ETF
LIT invests in the full lithium cycle, from mining and refining to battery production and EV manufacturing. It tracks the Solactive Global Lithium Index, with top holdings including Rio Tinto, Albemarle, and Tesla, as well as major battery makers like Samsung SDI.
Read more on LIT →
